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Abstract 
CD40 ligand (CD40L) acts as an immune modulator in activated T cells, and mutations in the 
extracellular domain are associated to X-linked hyper IgM syndrome. A role for platelet CD40L in 
mediating thrombotic and inflammatory processes in atherosclerosis has also been reported. Using the 
Cre/loxP recombination technology we generated four knockout lines of mice with deletion of the Cd40lg 
gene restricted to the hematopoietic system. Mouse lines with expression of Cre recombinase driven by 
the Tie2, Vav1, or CD4 promoters showed in vivo ablation of Cd40lg in leukocytes and platelets. In 
contrast, in mice with Cre expression driven by the megakaryocyte lineage-restricted Pf4 promoter, 
abolition of CD40L expression was observed in megakaryocytes cultured in vitro, but not in circulating 
platelets. Characterization of these animals revealed reduced in vivo thrombogenesis and defective 
activation of washed CD40L-deficient platelets, suggesting that membrane-bound CD40L is involved in 
the control of haemostasis acting as a platelet co-activator. In addition, we report the practically absence 
of CD40L in mouse and human endothelial cells, as well as the detection of an exon 3-deleted CD40L 
transcript in both platelets and leukocytes of mouse and human origin. Finally, compared with their 
corresponding littermate “floxed” controls, Cre+ mice carrying CD40-deficient leukocytes did not exhibit 
increased IgM levels, and reduction of IgA and IgG levels was statistically significant only in Tie2-Cre+ 
mice, suggesting that expression of CD40L in an earlier developmental step may be determinant in the 
regulation of the class switch recombination process. 
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Introduction 
The ligand of the CD40 receptor, CD40L, is a type II membrane glycoprotein of the tumor necrosis 
factor ligand (TNFL) superfamily composed of 215 amino acids distributed in three functional domains: a 
22 AA intracellular domain, a 24 AA transmembrane domain, and a cysteine-rich extracellular domain 
containing 215 AA. The sandwich structure of the TNFL homology domain in the extracellular region 
allows the typical trimeric organization of the members of this family of proteins (Shimadzu et al. 1995). 
Besides the complete 39 kDa CD40L molecule bound to the plasma membrane, there is a soluble 18 kDa 
form (sCD40L) that can associate with the complete form of the protein in biologically active 
heterotrimeric complexes (Graf et al. 1995). 
The role of CD40L as an immune modulator is well known. It has been implicated in several immune 
events including B cell proliferation, differentiation, isotype switching, regulation of stimulatory 
molecules, activation of antigen presenting cells and modulation of T cell priming (Elgueta et al. 2009). 
CD40L is also involved in haematopoietic development, including stem and progenitor cells (HSPCs), 
and it plays a critical role in the differentiation of naïve CD4+ T-cells into different T helper subsets 
(Seijkens et al. 2010). In humans, mutations in the extracellular domain of CD40L give rise to a rare 
immunodeficiency disorder, the X-linked hyper-IgM syndrome, characterized by increased susceptibility 
to infections and defective Ig isotype switching, resulting in low or undetectable serum levels of IgG and 
IgA, and normal or elevated IgM (Aruffo et al. 1993). 
Besides its expression in activated CD4+ T cells, CD40L is also found in a broad range of cells 
including T cells, B cells, basophils, eosinophils, NK cells, macrophages, dendritic cells, and endothelial 
cells (Mach et al. 1997; Schonbeck et al. 2000).  Moreover, CD40L is constitutively expressed in 
megakaryocytes, and activated platelets appear to be the primary source of plasma sCD40L (Henn et al. 
1998; Inwald et al. 2003). Emerging evidences suggest that platelet CD40L is involved in the adaptive 
immune response (Elzey et al. 2011) and, also, it may contribute to inflammatory diseases, including 
atherosclerosis (Nurden 2011; Hassan et al. 2012). Moreover, platelet CD40L has been reported to 
stabilize arterial thrombi through a mechanism involving interaction with αIIbβ3 integrin (Andre et al. 
2002b). Many of these studies were performed using a total CD40L knockout mouse model (Xu et al. 
1994), the only CD40L-deficient mice so far reported. 
In this work, we intended to study the role of CD40L in different cell types. For this purpose, we have 
crossed a CD40L “floxed” mouse line (Nowakowski et al. 2011) with four different transgenic mice with 
restricted expression of Cre recombinase in the hematopoietic system, driven by Tie2 (the gene for tunica 
intima endothelial kinase 2), Vav1 (coding for a guanine nucleotide exchange factor), CD4 (cluster of 
differentiation 4), and Pf4 (coding for the platelet factor 4) promoters. These lines were selected because 
they express Cre recombinase at different developmental stages, therefore offering additional information 
on the possibility that CD40L-dependent developmental events could influence the functional response. 
Evaluation of in vivo thrombogenesis and CD40L-deficient platelet activation, as well as determination of 
serum Ig levels in mice carrying CD40L-deficient leukocytes, provide valuable data on the functional 
significance of CD40L expression. 
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Material and Methods 
 
Ethics Statement 
All experiments with animals were done in such a way as to minimize animal suffering, according to 
relevant national and international guidelines (“Guide for Care and Use of Laboratory at the Institute of 
Laboratory Animal Resources”). 
The ethics committee of the Center for Biological Research (CSIC) and the grant review board 
(ANEP) of the Spanish Ministry of Science and Technology specifically approved this study in 
accordance with the guidelines of the European Community Council Directive 86/609 EEC. 
 
Animals 
Mice used in all the experiments were maintained under controlled conditions of light and 
temperature. Cd40lgf/f::Pf4-Cre, Cd40lgf/f::Vav-Cre, and Cd40lgf/f::CD4-Cre littermates were generated 
on a mixed C57BL/6-129sv, and CD40Lf/f::Tie2-Cre on a mixed CD1 genetic background, and were 
backcrossed for 10 generations with C57BL/6 or CD1 mice, respectively. 
To generate mice with a restricted deletion of Cd40lg in endothelial and/or hematopoietic cells, mice 
homozygous for the floxed allele with exons 3-4 flanked by functional loxP sites (Fig. 1A), generated 
previously (Nowakowski et al. 2011), were crossed to Pf4-Cre mice (generated and kindly gifted by Dr. 
R.C. Skoda, University Hospital Basel, Switzerland) (Tiedt et al. 2007), Tie2-Cre mice (kindly gifted by 
Dr. J.L. de la Pompa, National Centre of Biotechnology, Madrid, Spain) (Kisanuki et al. 2001), Vav-Cre 
mice (generated and kindly gifted by Dr. D. Kioussis, National Institute for Medical Research, London, 
UK) (de Boer et al. 2003) and CD4-Cre mice (kindly gifted by Dr. M. Raspa (European Mouse Mutant 
Archive, Roma, Italy) (Lee et al. 2001). 
 
PCR genotyping 
Recombination of the Cd40lg gene region flanked by the loxP sequences was verified by PCR 
analysis of genomic DNA. Oligonucleotides loxP-S: 5’-TTTCACTCCAGGTGATGAGG-3’ 
(overlapping intron3-exon4 sequences) and AS-8774: 5’-AATCTAACGTCTCAGCGCCTAT-3’ that 
targets a sequence in intron 4 were used to verify the correct insertion of the right loxP sequence in 
“floxed” mice. The same antisense primer and S-5669: 5’-ATAAGCACCCACAAAACACACT-3’ 
located in intron 2 were used to confirm the deletion of a DNA fragment comprising exons 3 and 4 in 
genomic DNA from endothelial cells of Tie2-Cre+ and leukocytes of Vav1- and CD4-Cre+ mice. 
Deletion of exons 3-4 in genomic DNA from in vitro differentiated megakaryocytes was verified with 
oligonucleotides S-5669 and AS-9514: 5’-GTTAGGTCAATCTCTGGTTATCAC-3’ located in intron 4. 
For littermate genotyping, tail genomic DNA and oligonucleotides S-6012: 5’-
CCAGGGATTCCCAATTGCTAT-3’ and AS-6259: 5’-CAAAATTGGTAATAGCAACCTACC-3’ were 
used to verify amplification of a DNA fragment comprising the left loxP sequence, and identification of 
Cre+ mice was performed by amplification of a DNA fragment with a sense oligonucleotide targeting a 
sequence of the specific promoter and an antisense primer targeting the Cre gene sequence. 
	   5	  
 
RT-PCR analysis of CD40L expression 
Total RNA from in vitro differentiated mouse megakaryocytes, platelets, peripheral blood 
mononuclear cells (PBMCs), and CD4+ T cells, and from mouse and human endothelial cells, was 
obtained using the “High Pure RNA Isolation Kit” from Roche. After removing platelet-rich plasma, 
peripheral blood was layered onto Histopaque 1083 (Sigma) or LymphoPrep (Progen Biotechnik) for 
separation of mouse or human PBMCs, respectively. A magnetic bead-based kit from Miltenyi was used 
to isolate mouse CD4+ T cells from total blood previously treated with hypotonic buffer to lyse red cells. 
RT-PCR amplification with oligonucleotides S-ATG: 5’-GCATGATAGAAACATACAG-3’ located 
in exon 1 and AS-TGA: 5’-TGTTCAGAGTTTGAGTAAGCC-3’ located in exon 5 confirmed normal 
sized cDNA in in vitro differentiated megakaryocytes from “floxed” mice and the deletion of exons 2-3 in 
cells from Cre+ mice. 
Oligonucleotide pairs with a common antisense primer (AS-TGA) and sense primers S-WT: 5’-
TGCAAAAAGGTGATCAGAATC-3’ overlapping exons 3 and 4, S-KO: 5’-
GAAGACCTTGTCAAGTTCTACA-3’ overlapping exons 2 and 5, and S-Sp: 5’-
CTTGTCAAGGTGATGAGGA-3’ overlapping exons 2 and 4, were designed to amplify similarly sized 
products corresponding to the normal, exons-2-3-deleted, and exon-3-deleted transcripts, respectively. 
RT-PCR analysis was also performed in human platelets, PBMCs, umbilical vein endothelial cells 
(HUVEC), human microvascular endothelial cell line (HMEC-1), and blood outgrowth endothelial cells 
established from peripheral blood (BOEC), using the same AS-TGA primer, conserved in the human 
sequence, and sense primers S-hWT: 5’-TGCAAAAAGGTGATCAGAATC-3’ overlapping exons 3 and 
4, and S-hSp: 5’-GGCTTTGTGAAGGTGATCA-3’ overlapping exons 2 and 4, to amplify similarly-
sized products corresponding to the normal and exon-3-deleted transcripts, respectively. 
In all RT-PCR assays, amplification of a cDNA fragment of human or mouse β-actin was carried out 
in parallel to verify that equal amounts of RNA were used ensuring correct normalization of CD40L 
expression. 
All RT-PCR assays were carried out twice, with similar results, using two different mixtures of RNA 
from at least 3 animal of each genotype. 
 
In vitro differentiation of megakaryocytes 
Bone marrow cells were flushed from femurs and tibias with Tyrode's buffer, dissociated and cultured 
in IMDM with 5% fetal bovine serum, 50 ng/mL TPO, 2 mM L-glutamine, 50 U/mL penicillin, and 50 
µg/mL streptomycin. Megakaryocytes were recovered by passing the suspension through a discontinuous 
density gradient of albumin. 
 
Endothelial cell isolation and culture 
Mice lungs from Cd40lglox/lox and Cd40lg-/- littermates were collected, chopped, digested with 1 mg/ml 
collagenase A (Roche, 10103578001), filtered through a sterile 18G microlance, and sieved through a cell 
strainer with 70 µm nylon membrane pore (Beckton and Dickinson). The purification of endothelial cells 
was carried out by a single negative sorting with anti-CD16/32 antibody (BD Pharmigen, 553142) and a 
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single positive sorting with anti-ICAM2 antibody (BD Pharmigen, 553326), using Dynabeads sheep anti-
rat IgG (Invitrogen, 110.35) and a magnetic particle concentrator (DynamagTM-15, Invitrogen 123.01D). 
Endothelial cells were plated on gelatin-coated 60 mm dishes and cultured during 3 days in medium 
containing DMEM (Gibco, 41966), Hams F-12 (Lonza, BE12-615F), 100 UI/mL penicillin/100 µg/ml 
streptomycin (Gibco, 15070-063), 20% fetal bovine serum (Sigma F7520), 20 µg/ml endothelial cell 
growth supplement from bovine neural tissue (ECGS, Sigma E2759) and 0.1 mg/ml of heparin sodium 
salt (Sigma, H3393). Finally, trypsin-detached cells were labeled with anti-ICAM2-FITC antibody (BD 
Pharmigen, 557444) and analyzed in a Coulter flow cytometer model EPICS XL. Only cultures with 
percentages greater that 90% of endothelial cells were used. 
 
Flow cytometry analysis of surface expression of CD40L 
Cell suspensions from mouse spleens were prepared by mechanical dissociation. Debris was removed 
by sedimentation followed by filtration through a 70 µm cell strainer, centrifugation, and resuspension in 
DMEM-10% FCS. After cell counting, single-cell suspensions from three animals of each genotype were 
mixed for cell activation assays. Spleen single-cell suspension (107 cells) were incubated in the absence 
or presence of 50 ng/mL PMA and 1 µg/mL ionomycin and, then, washed and stained with anti-
CD40L(clon MR1)-PE and anti-CD4(clon GK1.5)-FITC (eBioscience) or isotype-matched antibodies as 
negative control for 15 minutes at 4ºC, washed, and analyzed in a Coulter flow cytometer model FC500. 
The experiment was carried out twice with similar results. 
 
Preparation and activation of washed platelets 
Citrated blood samples were obtained by cardiac puncture under isofluorane anesthesia. The blood 
was centrifuged at 100 g for 20 minutes at room temperature. Platelet-rich plasma was removed and 
centrifuged at 1300 g in the presence of 0.1 µg/mL prostacyclin and 0.02 U/mL apyrase (Sigma) for 5 
minutes at room temperature, and washed 3 times with modified Tyrode's buffer containing 0.1 µg/mL 
prostacyclin and 0.02 U/mL apyrase. The sedimented platelets were finally suspended in Tyrode's buffer 
containing 0.02 U/mL apyrase and rested for 30 minutes at 37°C prior to stimulation. 
The membrane content of surface receptors was determined in washed platelets incubated with FITC-
labeled rat anti-mouse integrin αIIbβ3 and GPVI (Emfret Analytics, Eibelstadt, Germany) or control 
isotype-matched mouse IgGs for 30 minutes at room temperature. The samples were then washed and 
analyzed by flow cytometry. 
To determine the extent of platelets activation, 25 µL of washed platelets (106 approximately) 
suspended in Tyrode's-buffer containing 1 mM CaCl2 were stimulated with 10 µM ADP plus 50 µM 
epinephrine, or 0.2-1 U/mL thrombin. Activation was assessed by determining P-selectin exposure and 
αIIbβ3 activation by flow cytometry with 5 µL of FITC-anti-P-selectin (Beckton and Dickinson) or PE-
anti-activated αIIbβ3 (JON/A, Emfret Analytics) moAbs. 
 
Thrombogenesis in vivo 
As previously reported (Pericacho et al. 2011), 100 µL of blood was collected from one of the jugular 
veins of anesthetized mice into a tube containing 10 µL of 0.129 M sodium citrate. A mixture of 
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collagen/epinephrine (150 ng collagen type I (Chronolog) and 15 ng epinephrine (SIGMA) per g of mice 
body weight) was then injected into the same vein and, after 2 minutes, blood was withdrawn from the 
other jugular vein as indicated above. The number of platelets in both samples was determined using a 
hemocytometer analyzer Abacus Junior (Diatron Messtechnik GmbH, Austria). 
 
Immunoglobulin measurement by flow cytometry 
Immunoglobulin detection in “floxed” and conditional knockout mice from VAV-Cre, Tie2-Cre and 
CD4-Cre lines was performed with the Mouse Immunoglobulin Isotyping panel 6plex kit (eBioscience, 
BMS815FF) by flow cytometry, following manufacturer´s instructions. Non-citrated blood was extracted 
by cardiac puncture of 12-week-old mice. Complete blood was stored overnight at 4ºC and, after 
centrifugation at maximum speed, serum was collected and used to detect IgA, IgG1, IgG2a, IgG2b, IgG3 
and IgM immunoglobulins. Results obtained were analyzed with FlowCytomix Pro Software 
(eBioscience) to determine immunoglobulin concentration. 
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Results 
 
CD40L expression in mouse lines with conditional knockout of CD40L in hematopoietic cells 
To study the functional consequences of conditional knockout of CD40L, mice bearing two copies of 
the Cd40lg floxed allele (Fig. 1A) generated as previously described (Nowakowski et al. 2011) were 
mated with transgenic mouse lines expressing Cre recombinase driven by the promoters of three different 
genes that are expressed in T cells: Tie2 (the gene for tunica intima endothelial kinase 2), Vav1 (coding 
for a guanine nucleotide exchange factor), and CD4 (cluster of differentiation 4). The Tie2-Cre line 
(Kisanuki et al. 2001) produces Cre recombinase in endothelial cells and their progeny, including 
hematopoietic stem cells (HSC) and blood cells (Hsu et al. 2000); the Vav-iCre line (de Boer et al. 2003) 
expresses the Cre recombinase specifically in hematopoietic cells but only after HSC formation (He et al. 
2008); and the CD4-Cre line allows the Cre-recombinase to act on a later step of T cell development, the 
CD4+ T cells (Lee et al. 2001), and also in an early step in megakaryocyte maturation (Basch et al. 1996). 
Using genomic DNA from endothelial cells and leukocytes, we verified the correct insertion of right loxP 
sequence in “floxed” mice and the deletion of a DNA fragment comprising exons 3 and 4 in Cre+ mice 
(Fig. 1B-C). 
We assessed CD40L expression by RT-PCR analysis of the CD40L transcripts. We then designed 
oligonucleotide pairs consisting of a common antisense primer located in exon 5 and specific sense 
primers to amplify the normal or the deleted transcript. As shown in Fig. 2, in the three mouse lines, 
amplification of the normal transcript using a sense primer overlapping exons 2 and 3 was detected in 
platelets and leukocytes from control “floxed” mice, but not from Cre+ mice. In contrast, amplification 
with a sense primer overlapping exons 2 and 5 allowed detection of the deleted transcript only in Cre+ 
mice. Ablation of the Cd40lg gene in all these animals has not apparent effect on phenotype. The rates of 
growth and fertility were normal and no significant differences were detected in hemogram counts (Table 
S1). 
In order to demonstrate the absence of CD40L protein in targeted cells, spleen cell suspensions from 
“floxed” and Cre+ mice were stimulated with PMA/ionomycin and the surface expression of CD40L was 
determined in CD4+ cells by flow cytometry. As shown in Fig. 3, for all three Cre lines, CD40L was 
clearly detected in “floxed” mice but not in Cre+ mice. 
We also generated a fourth mouse line by mating Cd40lg f/f mice with mice expressing Cre-
recombinase under the control of platelet factor 4 promoter (Pf4) (Tiedt et al. 2007). In contrast to the 
other mouse lines, the results from semiquantitative RT-PCR analysis in platelets revealed an inefficient 
Cre-mediated recombination. As shown in Fig. 3A, the deleted transcript was detected in Cre+ mice only 
after 40 cycles of PCR amplification. Consistent with the scarce amount of the mutant transcript, amounts 
of amplification products of the normal transcript were similar to those obtained in “floxed” mice. 
However, efficient Cre-mediated excision of the floxed allele was demonstrated in in vitro cultured 
megakaryocytes. We verified the deletion of a DNA fragment comprising exons 3 and 4 in Cre+ mice 
(Fig. 1D). Moreover, amplification with oligonucleotides located in exons 1 and 5 yielded a cDNA 
product corresponding to the normal transcript in megakaryocytes from “floxed” mice and a product 
corresponding to the transcript with deletion of exons 3-4 in cells from Cre+ mice (Fig. 3B). 
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Expression of an exon 3-deleted transcript of CD40L in both platelets and leukocytes 
During sequence analysis of RT-PCR products we detected an alternative form of CD40L transcript 
lacking exon 3 in platelets from mice bearing the Cd40lg floxed allele. In order to rule out the possibility 
of aberrant splicing caused by the presence of the 5’-loxP site, introduced 48 bp upstream of exon 3, we 
designed a sense primer overlapping exons 2 and 4 and analyzed by RT-PCR the relative expression of 
this alternative transcript. Results in Fig. 5A show that the exon 3-deleted CD40L transcript is present in 
both platelets and leukocytes from wild type mice of the same genetic backgrounds. In addition, it was 
also found in platelets and leukocytes of human origin (Fig. 5B). When compared with expression of the 
full-length transcript, we estimated that it represents a minor proportion (less than 5%) of total CD40L 
transcripts (Fig. 5). Skipping of exon 3 results in frameshift and premature stop codon 36 bp downstream. 
Thus, the aberrant transcript is predicted to encode a protein carrying an abnormal and severily truncated 
amino acid composition at the extracellular aminoterminal region. 
 
CD40L expression in mouse and human endothelial cells 
Early reports on CD40L expression have led to the general consent that CD40L is expressed in 
endothelial cells, at least of human origin (Mach et al. 1997; Schonbeck et al. 2000). In the present study, 
RT-PCR of total RNA from mouse lung vascular endothelial cells (MLEC) revealed that CD40L 
expression is not detectable after 45 cycles of amplification (Fig. 6A). We also failed to detect CD40L in 
total RNA from human umbilical vascular endothelial cells (HUVEC) and human blood outgrowth 
endothelial cells (BOEC) (Fig. 6B). It was only detectable, although scarcely when compared with its 
expression in leukocytes and platelets, in RNA from human dermal microvascular endothelial cells 
(HMEC-1) (Fig. 6B). 
 
In vivo thrombogenesis and in vitro platelet activation in CD40L knockout mice 
Studies carried out with the Cd40lg -/- mouse model (Xu et al. 1994) show a normal hemostasis. 
However, alteration in thrombus formation (Andre et al. 2002a) has been reported indicating a role of 
CD40L in protection against thrombosis. Platelets seem to be the main source of sCD40L and a decrease 
in the concentration of sCD40L inside the thrombus has been related with the thrombogenic defect of the 
Cd40lg -/- mice (Prasad et al. 2003). We performed in vivo thrombogenesis experiments by inducing 
pulmonary thromboembolism by intravenous administration of collagen plus epinephrine. Results 
summarized in Fig. 7 indicate that Vav-iCre+ mice display a significantly smaller decrease in circulating 
platelets two minutes after the administration of agonists than Vav-iCre- animals, indicating that CD40L-
deficient mice have a decreased thromboembolic response. However, no significant differences were 
observed in Tie2-Cre+ and CD4-Cre+ mice. 
A role for CD40L in fibrin clot formation can be excluded in view that Cre+ mice of the three lines 
showed similar values of prothrombin time (PT) and activated partial thromboplastin time (aPTT) than 
their littermate “floxed” controls (Table S2). 
Washed CD40L-deficient platelets obtained from the three mouse lines under study show a significant 
decrease of αIIbβ3 activation in response to thrombin, as determined by the binding of JON/A antibody 
	   10	  
that selectively binds to the high affinity conformation of mouse αIIbβ3 (Fig. 8A). Although platelet 
activation in response to ADP/epinephrine was also reduced in all Cre+ mice, the effect was statistically 
significant only in platelets from Vav-Cre+ mice. These mice also showed reduced P-selectin release after 
thrombin stimulation (Fig. 8B). These effects were not due to decreased surface expression of αIIbβ3 and 
GPVI receptors (Table S3). 
 
Serum immunoglobulin levels in CD40L deficient mice 
One of the characteristic features of X-linked hyper IgM syndrome is the alteration in the serum 
immunoglobulin phenotype (Aruffo et al. 1993). Serum from patients contains elevated levels of IgM, 
and low to undetectable levels of other immunoglobulin isotypes, including IgG. To determine whether 
CD40L deficiency associates in mice with a similar phenotype, we determined the immunoglobulin levels 
in serum from eight control “floxed” and eight Cre+ mice of each Cre line. Table 1 shows that the 
alterations in the serum levels of Igs varied in the different mouse lines. Tie-Cre+ mice have levels of 
IgA, IgG1, IgG2a, IgG3 and IgM significantly lower than their littermate “floxed” controls. However, in 
the Vav-iCre line only IgM levels are significantly reduced while a subset of IgG (IgG1) is significantly 
increased. Furthermore, in the CD4-Cre line, CD40L knockout does not induce remarkable variations of 
any of the Igs tested. 
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Discussion 
At present, the only available mouse line deficient for CD40L is a total knockout model generated by 
replacing a 506-bp DNA fragment containing part of exon 4 with the pCM1 gene in an opposite direction 
(Xu et al. 1994). These mice have been used to explore the role of CD40-CD40L interaction on different 
aspects of the immune response as well as on atherogenic and inflammatory processes (Wolf et al. 2012; 
Lievens et al. 2010). 
We have recently generated a Cd40lg “floxed” mouse line in which Cd40lg alleles carry loxP sites 
flanking a DNA fragment comprising exons 3-4 (Nowakowski et al. 2011). In the present study, we have 
crossed these animals with three different Cre mouse lines (Tie2-Cre, Vav-iCre, and CD4-Cre) in order to 
explore the effect of restricting expression of CD40L at different steps of hematopoietic development. 
Efficiency of Cre-mediated ablation of Cd40lg in lymphocytes and platelets was assessed by RT-PCR 
analysis of CD40L transcripts. The normal transcript was not found in Cre+ mice, indicating efficient 
Cre-mediated recombination. Although we have not performed a precise quantitative determination of the 
CD40L-mRNA levels, the semiquantitative RT-PCR analysis indicates that the amounts of normal and 
deleted transcripts detected in cells from “floxed” and Cre+ mice, respectively, were similar. The mutant 
transcript is predicted to produce a protein carrying an abnormal and severely truncated extracellular 
region lacking the CD40 receptor-binding domain. A similarly truncated CD40L protein has been 
described previously in a patient causing X-linked hyper IgM syndrome through a dominant negative 
inhibition of CD40L trimeric complex formation (Zhu et al. 2001). Although, given the relatively high 
expression of the deleted transcript in our Cre+ mice, we cannot exclude that these animals express 
significant amounts of a dysfunctional CD40L protein, the flow cytometry analysis of CD4+ T cells 
stimulated with PMA/ionomycin indicates that CD40L is practically absent in cells from Cre+ mice. 
The role of platelet CD40L in thrombosis (Inwald et al. 2003; Prasad et al. 2003) and, also, its 
emerging function in both innate and adaptive immunity (Semple et al. 2011; Li et al. 2012), 
inflammation (Nurden 2011; Wolf et al. 2012), and atherosclerosis (Elzey et al. 2011; Wolf et al. 2012; 
Lievens et al. 2010; Semple et al. 2011; Li et al. 2012) prompted us to develop a mouse line with 
megakaryocytic specific ablation of CD40L, by using Pf4-Cre mice. Although the floxed Cd40lg allele 
was efficiently excised in in vitro differentiated megakaryocytes from Pf4-Cre+ mice, we found that 
circulating platelets from control “floxed” and Cre+ mice carry similar amounts of the CD40L normal 
transcript, suggesting a practically total failure of Cre to induce recombination in vivo. Other genes 
expressed in megakaryocyte/platelet, like β1 integrin or podocalyxin, have been successfully excised 
using the same Pf4-Cre transgenic mouse line (Tiedt et al. 2007; Pericacho et al. 2011), which discards a 
deficient expression of Cre recombinase. Persistence of a Cre-recombination episomal product has been 
reported to be the cause of absolute lack of protein loss in an inducible Cre mouse model where efficient 
DNA deletion occurred (Turlo et al. 2010). This possibility is unlikely in our case; although we have not 
confirmed that loxP alleles were not appropriately targeted during in vivo differentiation of 
megakaryocytes, the almost undetectable levels of deleted transcripts in platelets (Fig. 4A), compared 
with those obtained in the other Cre mouse lines (Fig. 2A-C), points to a deficient Cre-mediated excision. 
Thus, these results indicate that, for unexplained reasons, Pf4-driven Cre expression fails to excise this 
Cd40lg floxed allele during in vivo differentiation of megakaryocytes, and highlight the need of validate 
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protein depletion in vivo for every novel Cre/loxP combination. 
The decreased pulmonary thrombogenic response observed in vivo in Vav-iCre+ mice supports the 
role of CD40L in thrombus formation and/or stability. This role has been claimed to be mediated by 
sCD40L in humans. Several pathologies involving thrombotic risk (hypercholesterolaemia, diabetes, 
stroke or acute coronary syndromes) show platelet activation and high levels of sCD40L (Tousoulis et 
al, 2010; Nurden, 2011). We show that activation of αIIbβ3 in response to thrombin was significantly 
reduced in washed platelets from the three Cre mouse lines. This effect was more pronounced in Vav-
iCre+ mice, which also showed deficient integrin activation upon ADP/epinephrine stimulation, reduced 
P-selectin exposure in response to thrombin, and a diminished thrombogenic response in vivo. These 
effects were not due to defective expression of αIIbβ3. Previous studies addressing the function of 
platelet CD40L have shown that the absence of CD40L impairs thrombus stability and delays arterial 
occlusion in vivo (Andre et al. 2002b; Prasad et al. 2003). However, isolated platelets stimulated with 
soluble CD40L (sCD40L) have yielded somewhat differing conclusions on CD40L-mediated platelet 
activation. Addition of sCD40L to platelets has been shown to promote CD40-mediated exposure of P-
selectin and granule release, but not platelet aggregation (Inwald et al. 2003). By contrast, activation of 
αIIbβ3 and platelet aggregation under high shear, mediated by the binding of sCD40L to αIIbβ3, has 
been reported after addition of sCD40L to CD40-deficient platelets (Andre et al. 2002b; Prasad et al. 
2003). Our experiments showing defective activation of washed CD40L-deficient platelets add further 
insights into the functional significance of platelet CD40L and suggest that membrane-bound CD40L is 
involved in the control of hemostasis acting as a platelet co-activator. 
In humans, mutations in the Cd40lg gene cause X-linked hyper IgM (X-HIGM) immunodeficiency 
syndrome, characterized by recurrent infections, low levels of serum IgG, IgA and IgE, and elevated or 
normal levels of serum IgM due to defective immunoglobulin isotype switching (Levy et al. 1997). 
Consistent with a previous study carried out in a total knockout mouse model (Xu et al. 1994), 
conditional knockout of the Cd40lg gene did not associate to increased levels of serum IgM in any of the 
three mouse lines expressing Cre in hematopoietic cells. By contrast, IgM levels were significantly 
reduced in Tie2-Cre+ and Vav-iCre+ mice. In consonance with these data, a recent report has revealed 
that about 50% of X-HIGM patients do not present increased IgM and in approximately 6.4% of the cases 
the IgM levels are decreased, suggesting that patients with total hypogammaglobulinemia may not have 
undergone diagnostic procedures for X-HIGM and detection of Cd40lg mutations (Heinold et al. 2010). 
Determination of serum levels of IgA and IgG subclasses also yielded unexpected results. Vav-iCre+ and 
CD4-Cre+ mice showed no significant changes, and the decrease detected in Tie2-Cre+ mice, although 
significant, may not be sufficient to have functional relevance. It is known that CD40L is involved in 
haematopoietic development, including stem and progenitor cells (HSPCs), T-cell, B-cell, and dendritic 
cell progenitors, and it plays a critical role in the differentiation of naïve CD4+ T-cells into different T 
helper subsets (Seijkens et al. 2010). Expression of CD40L in one of these subpopulations, the T 
follicular helper cells, is thought to be essential to mediate antibody class switching through the 
interaction with its receptor, CD40, in mature B cells (Aversa et al. 1994). Our study shows that 
abolishing expression of CD40L at different steps of hematopoietic cell development does not seem to 
have a significant impact on class switch recombination suggesting that, at least in mouse, expression of 
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CD40L in an earlier stage of development may be determinant in the regulation of this process. The 
significant decrease of IgA and IgG in mice expressing Cre under the Tie2 promoter, activated earlier 
than Vav1 and CD4 promoters during development, supports this possibility. Alternatively, as observed 
in an increasing number of mouse models (Montagutelli 2000; Jelcick et al. 2011), it may reflect the 
difference between C57BL/6-129sv and CD1 genetic backgrounds. Finally, even in case the deleted 
CD40L transcript expressed in Cre+ mice was translated into a protein, the absence of CD40 binding-
domain would preclude its functionality to induce class switch recombination. 
Finally, it is worthy to mention that, in contrast to previous reports (Mach et al. 1997; Wagner et al. 
2004), we have failed to detect CD40L expression in mouse and human endothelial cells. Scarce RNA 
expression was only found in a human microvascular endothelial cell line (HMEC-1). Although CD40L 
expression could be upregulated in inflammatory contexts (Reul et al. 1997; Geraldes et al. 2006), our 
results suggest that endothelial CD40L has not functional relevance in basal conditions. 
In summary, we have established three novel mouse lines with conditional knockout of the Cd40lg 
gene in the hematopoietic system and verified the efficient Cre-mediated deletion of CD40L in targeted 
cells. In contrast, ablation of Cd40lg was only observed in in vitro differentiated megakaryocytes in a 
fourth mouse model with Cre expression restricted to the megakaryocyte lineage. Mice carrying CD40L-
deficient leukocytes do not exhibit increased levels of serum IgM, and reduction of IgA and IgG levels 
was statistically significant only in Tie2-Cre+ mice. Our results also show defective activation of washed 
CD40L-deficient platelets and reduced in vivo thrombogenesis, adding further insights into the functional 
significance of platelet CD40L. Finally, we report the practically absence of CD40L in mouse and human 
endothelial cells and, also, the detection of an exon 3-deleted CD40L transcript in both platelets and 
leukocytes of mouse and human origin. 
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Legends to the figures 
 
Figure 1. Gene targeting and conditional deletion of exons 3-4 of the Cd40lg gene. A) Restriction 
map of the targeting vector, floxed allele, and null allele. Open boxes represent exons numbered as 
indicated. Neomycin (neo) and thymidine kinase (tk) are positive and negative selection cassettes, 
respectively. Restriction sites: B, NotI; S, SpeI; X, XhoI; Ss, Sse8387I; A, AscI; E, EcoRI. The arrows 
indicate the location of oligonucleotides used for PCR genotyping. B) Oligonucleotides loxP-S (1) and 
AS-8774 (2) amplify a 589 bp DNA fragment in MLECs from “floxed” mice (lane 2) and in total 
leukocytes from CD4-Cre+ and “floxed” mice (lanes 5 and 6), but not in MLECs from Tie2-Cre+ (lane 
1), in total leukocytes from Vav1-Cre+ (lane 3), and in CD4+ leukocytes from CD4-Cre+ (lane 4) mice. 
C) Oligonucleotides S-5669 (3) and AS-8774 (2) amplify a 868 bp product in MLECs from Tie2-Cre+ 
mice (lane 1) and in total leukocytes from Vav1-Cre+ and CD4-Cre+ mice (lanes 3 and 4), but not in 
MLECs from “floxed” mice (lane 2) and in leukocytes from “floxed” mice (lane 5). D) Oligonucleotides 
S-5669 (3) and AS-9514 (4) amplify a 1608 bp product in in vitro differentiated megakaryocytes from 
PF4-Cre+ mice (lanes 1 and 2) but not from “floxed” mice (lanes 3 and 4). 
 
Figure 2. RT-PCR analysis of CD40L expression in platelets and leukocytes of mice expressing Cre 
recombinase under the control of Tie2, Vav1, or CD4 promoter. Total RNA from platelets (A, B, and 
C) PBMCs (D and E) and CD4+ T cells (F) of “floxed” (lanes 1) and Cre+ mice (lanes 2) was used for 
RT-PCR amplification of the wild type and deleted transcripts of CD40L, using a common antisense 
primer and specific sense primers, as described in “Methods”. The experiments were perfomed twice with 
similar results. 
 
Figure 3. Flow cytometry analysis of surface expression of CD40L in splenic CD4+ T cells. Spleen 
single-cell suspension (107 cells) were incubated without or with 50 ng/mL PMA plus 1 µg/mL 
ionomycin and, then, stained with anti-CD4-FITC and anti-CD40L-PE or isotype-matched antibodies as 
negative control, and analyzed by flow cytometry as described in “Methods”. Histograms from a cell 
mixture of three mice in each group are shown. For clarity, histograms of untreated cells have been 
omitted. The experiment was carried out twice with similar results. 
 
Figure 4. RT-PCR analysis of CD40L expression in platelets and in vitro differentiated 
megakaryocytes of mice expressing Cre under the control of Pf4 promoter. A) Total RNA from 
platelets of wild type (lanes 1), “floxed” (lanes 2) and Cre+ mice (lanes 3) was used for RT-PCR 
amplification of the wild type and deleted transcripts of CD40L, using a common antisense primer and 
specific sense primers, as described in “Methods”. B) Total RNA from bone marrow cells differentiated 
to megakaryocytes was used for RT-PCR amplification of CD40L using sense and antisense primers 
located in exons 1 and 5, respectively, as described under “Methods”. The experiments were perfomed 
twice with similar results. 
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Figure 5. Detection of an exon 3-deleted transcript in platelets and leukocytes of mouse and human 
origin. Total RNA from platelets and PBMCs of mouse (A) and human (B) was used for RT-PCR 
amplification of cDNA fragments of CD40L corresponding to the full-length and exon 3-deleted 
transcripts, using a common antisense primer and specific sense primers as described under “Methods”. 
The experiments were perfomed twice with similar results. 
 
Figure 6. RT-PCR analysis of CD40L expression in endothelial cells of mouse and human origin. 
Total RNA from mouse leukocytes and lung endothelial cells (MLEC) (A) and from human leukocytes 
and endothelial cell lines (B) was used for RT-PCR analysis of CD40L expression as described under 
“Methods”. Abbreviations used: HUVEC, human umbilical endothelial cells; HMEC-1, human 
microvascular endothelial cells; BOEC, blood outgrowth endothelial cells. The experiments were 
perfomed twice with similar results. 
 
Figure 7. Relative fall in circulating platelets induced by the i.v. administration of 
collagen/epinephrine. Blood was collected from the jugular vein followed by i.v. injection of a mixture 
of collagen and epinephrine and, after two minutes, blood was withdrawn from the contralateral vein and 
the platelet count in both samples determined using a hemocytometer as described in “Methods”. The 
data represent the percent of reduction in the number of circulating platelets and are mean values +/- SEM 
of at least 6 animals. The Anderson-Darling test was used to verify normal distribution of data. The 
significance of the results was assessed by two tailed, unpaired, t-test. ns, non significant. 
 
Figure 8. Platelet activation of CD40L-deficient platelets. Washed platelets were estimulated with 10 
µM ADP/ 50 µM epinephrin (Epi) or 0.2-1 U/mL thrombin (TB), and the binding of specific antibodies 
againts activated  αIIbβ3 (A) or P-selectin (B) was determined by flow cytometry. The results are mean 
values +/- SEM of at least 6 animals. The Anderson-Darling test was used to verify normal distribution of 
data. By two tailed, unpaired, t-test: * P<0.05; ** P<0.005; ns, non significant. 
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RBC 7.3±0.3 7.6±0.2 6.9±0.2 7.1±0.3 7.2±0.4 7±0.4 
HGB 10±0.5 11±0.3 9.6±0.4 10±0.5 10±0.5 9.5±0.5 
HCT 31±1.6 32±0.9 29±0.1 30±1.1 29±1.5 28±1.7 
MVC 42±0.4 43±0.3 42±0.3 42±0.4 41±0.3 41±0.3 
RDWc 17±0.2 17±0.2 18±0.3 18±0.2 17±0.2 17±0.3 
MCH 14±0.2 15±0.2 14±0.3 14±0.3 14±0.3 14±0.4 
MCHC 33±0.5 34±0.6 33±0.7 33±0.7 34±0.7 34±0.8 
PLT 290±20 251±22 340±20 339±25 287±16 269±26 
WBC 4.3±0.4 5.1±0.5 4.3±0.4 3.2±0.3 4±0.5 4±0.3 
LY 93±1.8 93±1.9 90±1.5 92±1 91±2.7 88±5 
MI  4±1.1 2.4±0.4 3.4±0.6 3.7±0.7 2.4±0.6 2.7±0.4 
GR 5±1.4 6±1.9 8.1±1.3 7.1±1.5 6.7±2.3 4.3±1.4 
 
 
 
 
Table S1. Hemograms were determined in citrated blood samples obtained by cardiac puncture, using an 
automatic hemocytometer model Abacus Junior (Diatron, Diatron Messtechnik GmbH, Austria). 
Abbreviations (units): RBC, Red blood cells (M/nl); HGB, hemoglobin (g/dl); HCT, hematocrit (%); 
MVC, mean corpuscular value (fl); RDW, red cell distribution width (%); MCH, mean corpuscular 
hemoglobin (pg); MCHC, mean corpuscular hemoglobin concentration (%); PLT, platelets (k/ml); WBC, 
white blood cells (k/nl); LY, lymphocytes (%); MI, monocytes (%); GR, granulocytes (%). The values are 
mean ± standard error. There are no statistically significant differences as calculated by two tailed, 
unpaired t-test. 
 Time (seconds) of 
 
PT aPTT 
Cre- (n) 18±1.6 (15) 32±5 (15) 
Cre+ (n) 17±0.9 (14) 46±10 (13) Tie2-Cre 
P  0.65 0.32 
 
Cre- (n) 25±4.7 (11) 89±28 (9) 
Cre+ (n) 19.6±2.3 (11) 46.5±12 (11) Vav-iCre 
P 0.31 0.15 
 
Cre- (n) 25±4.2 (14) 27.6±4.3 (14) 
Cre+ (n) 21±4.2 (12) 33.4±6 (13) CD4-Cre 
P 0.52 0.39 
 
 
Table S2. Determination of prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). PT and aPTT were measured in plasma samples using a 
coagulometrer model Start4 (Diagnostica Stago). Briefly, citrated-blood samples obtained 
through cardiac puncture were centrifuged at 2,500 g for 15 min and plasma was collected. PT 
time was determined after addition of 100 µl of Neoplastine CI Plus reagent (Diagnostica Stago) 
to a final volume of 50 µl of plasma. To measure aPTT time, 50 µl of plasma were mixed with 
the same volume of commercial aPTT Reagent (Diagnostica Stago) in the presence of CaCl2 
according to manufacture´s intructions. 
The values are mean ± standard error, being n the number of observations. The value of P was 
calculated by two tailed, unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Platelet content of surface receptors. Washed platelets were incubated with FITC-
labeled rat anti-mouse integrin αIIbβ3 and GPVI (Emfret Analytics, Eibelstadt, Germany) or 
control isotype-matched mouse IgGs for 30 minutes at room temperature. The samples were 
then washed and analyzed by flow cytometry. Values are mean channel fluorescence arbitrary 
units. The results are means ±SEM of 4 different observations in duplicate. Not significant 
differences were detected between control and CD40L-deficient platelets. 
 
 
 αIIbβ3 GPVI 
Cre- 113±13 5.4±0.4 Tie2-Cre Cre+ 96±3 5.2±0.2 
Cre- 78±3 4.9±0.3 Vav-iCre Cre+ 79±2.5 5.2±0.2 
Cre- 83±2.3 4.3±0.03 CD4-Cre Cre+ 80±4 4.6±0.2 
